Literature DB >> 10780786

Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines.

C Julian-Reynier1, F Eisinger, J P Moatti, H Sobol.   

Abstract

After a BRCA mutation has been identified in the context of hereditary breast/ovarian cancer (HBOC), mammographic screening and prophylactic surgery are two of the main options available to those responsible for the clinical management of healthy women. The aim of this study was to describe the attitudes of specialists towards the clinical management of women with an HBOC risk: this information was collected prior to the publication of the recent French guidelines. A random national sample of 1169 French surgeons, gynaecologists and obstetricians was surveyed using a mailed questionnaire, to which 700 of these physicians (60%) responded. When dealing with a BRCA mutated woman, 88.6% of the respondents said they would recommend mammographic screening, but only 27.1% would recommend that it should be carried out annually from the age of 30 years onwards, as recommended in the French guidelines; 10.9% would find it acceptable to propose prophylactic mastectomy from the age of 30 years, and 22.9% would find it acceptable to propose prophylactic oophorectomy from the age of 35 years. The specialists who agreed with recommending breast/ovarian cancer genetic testing also had more positive attitudes towards prophylactic mastectomy (adj OR = 3.4, 95% CI = 1.4-8.2), as did those who had previously recommended prophylactic mastectomy when gene testing was not yet available (adj OR = 2.06, 95% CI = 1.23-3.44). The respondents' attitudes towards prophylactic oophorectomy and mastectomy were significantly associated (adj OR = 3.9; 95% CI = 2.3-6.5). Previous recommendation of prophylactic mastectomy was associated (P < 0.01) with a higher level of knowledge of breast/ovarian cancer genetics and with medical practice in this field. French physicians' attitudes towards mammographic screening and prophylactic surgery were not in complete agreement with the subsequently published French guidelines, the impact of which has now to be considered. Constantly evolving knowledge about the efficacy of preventive intervention will give practitioners new elements to integrate into their counselling.

Entities:  

Mesh:

Year:  2000        PMID: 10780786     DOI: 10.1038/sj.ejhg.5200418

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  11 in total

1.  Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing.

Authors:  Vardit Kram; Tamar Peretz; Michal Sagi
Journal:  Fam Cancer       Date:  2006-05-25       Impact factor: 2.375

2.  Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives.

Authors:  Audrey Ardern-Jones; Regina Kenen; Elly Lynch; Rebecca Doherty; Rosalind Eeles
Journal:  Hered Cancer Clin Pract       Date:  2010-01-12       Impact factor: 2.857

3.  Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.

Authors:  S U Dhar; H P Cooper; T Wang; B Parks; S A Staggs; S Hilsenbeck; S E Plon
Journal:  Breast Cancer Res Treat       Date:  2011-04-05       Impact factor: 4.872

4.  The process of deciding about prophylactic surgery for breast and ovarian cancer: Patient questions, uncertainties, and communication.

Authors:  Robert Klitzman; Wendy Chung
Journal:  Am J Med Genet A       Date:  2010-01       Impact factor: 2.802

5.  Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.

Authors:  Bettina Meiser; Melanie A Price; Phyllis N Butow; Janan Karatas; Judy Wilson; Louise Heiniger; Brandi Baylock; Margaret Charles; Sue-Anne McLachlan; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

6.  Comparison of physicians' and cancer prone women's attitudes about breast/ovarian prophylactic surgery. Results from two national surveys.

Authors:  F Eisinger; D Stoppa-Lyonnet; C Lasset; P Vennin; F Chabal; C Noguès; J P Moatti; H Sobol; C Julian-Reynier
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

7.  Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.

Authors:  Lee Galmor; Rinat Bernstein-Molho; Miri Sklair-Levy; Dana Madoursky-Feldman; Dov Zippel; Yael Laitman; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2020-09-30       Impact factor: 4.872

8.  International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly A Metcalfe; Daphna Birenbaum-Carmeli; Jan Lubinski; Jacek Gronwald; Henry Lynch; Pal Moller; Parviz Ghadirian; William D Foulkes; Jan Klijn; Eitan Friedman; Charmaine Kim-Sing; Peter Ainsworth; Barry Rosen; Susan Domchek; Teresa Wagner; Nadine Tung; Siranoush Manoukian; Fergus Couch; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2008-05-01       Impact factor: 7.396

9.  Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations.

Authors:  Claire Julian-Reynier; Julien Mancini; Emmanuelle Mouret-Fourme; Marion Gauthier-Villars; Valérie Bonadona; Pascaline Berthet; Jean-Pierre Fricker; Olivier Caron; Elisabeth Luporsi; Catherine Noguès
Journal:  Eur J Hum Genet       Date:  2011-01-26       Impact factor: 4.246

10.  Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation.

Authors:  Kelly A Metcalfe; Parviz Ghadirian; Barry Rosen; William Foulkes; Charmaine Kim-Sing; Andrea Eisen; Peter Ainsworth; Doug Horsman; Christine Maugard; Diane Provencher; André Robideaux; Dawna Gilchrist; Albert Chudley; Edmond G Lemire; Susan Armel; Amy Finch; Ping Sun; Steven A Narod
Journal:  Open Med       Date:  2007-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.